Meloxicam/Rizatriptan (Symbravo) vs Sumatriptan/naproxen sodium (Treximet)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Migraine
Shared mechanisms: 5-HT1B/1D receptor · Nonsteroidal Anti-inflammatory Drug · full Migraine pipeline
Meloxicam/Rizatriptan (Symbravo)
Marketed by Axsome Therapeutics
NCT03896009 · Phase 3 · completed
The trial was a large, randomized, double-blind, placebo- and active-controlled study with 1,594 participants. Both prespecified primary clinical endpoints were statistically significant in favor of the meloxicam/rizatriptan combination versus placebo: 2-hour headache pain freedom and absence of the most bothersome symptom.
Reported efficacy
Long-term Safety of Chronic Intermittent Use of AXS-07 (Up to 12 months): Long-term Safety of Chronic Intermittent Use of AXS-07 (Up to 12 months): AXS-07 — Subjects with any TEAEs: 293 Participants; Subjects with suspected to be drug-related TEAEs: 118 Participants; Subjects with serious TEAEs: 8 Participants; Subjects with TEAEs that led to drug withdrawal: 10 Participants; Subjects with TEAEs that led to withdrawal from study: 13 Participants; Subjects with TEAEs that resulted in death: 0 Participants (not_applicable)
Result source: NCT04068051
Sumatriptan/naproxen sodium (Treximet)
Marketed by Azurity Pharmaceuticals and partners
NCT00488514 · Phase 3 · completed
The study was nonrandomized, open-label, and had no placebo or active comparator, although 656 adolescents were enrolled. Its posted primary safety endpoint found drug-related adverse events in 170 of 622 treated participants, but the uncontrolled design cannot establish how Treximet compares with no treatment or another migraine medicine.
No aligned efficacy figure on record for this race.
Results for Migraine
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Meloxicam/Rizatriptan (Symbravo): registry results are on file for Migraine, but their comparison mappings are not yet available.
Sumatriptan/naproxen sodium (Treximet): registry results are on file for Migraine, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Meloxicam/Rizatriptan (Symbravo)'s landscape · Sumatriptan/naproxen sodium (Treximet)'s landscape